vs
Side-by-side financial comparison of PCB BANCORP (PCB) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
PCB BANCORP is the larger business by last-quarter revenue ($29.2M vs $28.1M, roughly 1.0× ARS Pharmaceuticals, Inc.). On growth, PCB BANCORP posted the faster year-over-year revenue change (11.3% vs -67.6%).
PCB Bank is an American community bank that focuses on the Korean-American community based in California and offers commercial banking services. It has branches in 8 states and is the third largest Korean American Bank after Bank of Hope and Hanmi Bank.
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
PCB vs SPRY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $29.2M | $28.1M |
| Net Profit | — | $-41.3M |
| Gross Margin | — | — |
| Operating Margin | 45.0% | -147.6% |
| Net Margin | — | -147.1% |
| Revenue YoY | 11.3% | -67.6% |
| Net Profit YoY | — | -182.8% |
| EPS (diluted) | $0.65 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $29.2M | $28.1M | ||
| Q3 25 | $30.4M | $32.5M | ||
| Q2 25 | $29.3M | $15.7M | ||
| Q1 25 | $26.9M | $8.0M | ||
| Q4 24 | $26.2M | $86.6M | ||
| Q3 24 | $25.3M | $2.1M | ||
| Q2 24 | $24.2M | $500.0K | ||
| Q1 24 | $23.9M | $0 |
| Q4 25 | — | $-41.3M | ||
| Q3 25 | $11.4M | $-51.2M | ||
| Q2 25 | $9.1M | $-44.9M | ||
| Q1 25 | $7.7M | $-33.9M | ||
| Q4 24 | — | $49.9M | ||
| Q3 24 | $7.8M | $-19.1M | ||
| Q2 24 | $6.3M | $-12.5M | ||
| Q1 24 | $4.7M | $-10.3M |
| Q4 25 | 45.0% | -147.6% | ||
| Q3 25 | 52.3% | -163.7% | ||
| Q2 25 | 43.3% | -302.9% | ||
| Q1 25 | 40.2% | -466.3% | ||
| Q4 24 | 39.3% | 54.5% | ||
| Q3 24 | 42.2% | -1051.6% | ||
| Q2 24 | 36.3% | -3068.0% | ||
| Q1 24 | 27.2% | — |
| Q4 25 | — | -147.1% | ||
| Q3 25 | 37.5% | -157.4% | ||
| Q2 25 | 31.0% | -285.6% | ||
| Q1 25 | 28.8% | -425.7% | ||
| Q4 24 | — | 57.7% | ||
| Q3 24 | 30.8% | -925.0% | ||
| Q2 24 | 25.9% | -2503.2% | ||
| Q1 24 | 19.6% | — |
| Q4 25 | $0.65 | $-0.41 | ||
| Q3 25 | $0.78 | $-0.52 | ||
| Q2 25 | $0.62 | $-0.46 | ||
| Q1 25 | $0.53 | $-0.35 | ||
| Q4 24 | $0.46 | $0.52 | ||
| Q3 24 | $0.52 | $-0.20 | ||
| Q2 24 | $0.43 | $-0.13 | ||
| Q1 24 | $0.33 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $207.1M | $245.0M |
| Total DebtLower is stronger | — | $96.4M |
| Stockholders' EquityBook value | $390.0M | $114.3M |
| Total Assets | $3.3B | $327.7M |
| Debt / EquityLower = less leverage | — | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $207.1M | $245.0M | ||
| Q3 25 | $369.5M | $288.2M | ||
| Q2 25 | $263.6M | $240.1M | ||
| Q1 25 | $214.3M | $275.7M | ||
| Q4 24 | $198.8M | $314.0M | ||
| Q3 24 | $193.1M | $204.6M | ||
| Q2 24 | $177.6M | $218.7M | ||
| Q1 24 | $239.8M | $223.6M |
| Q4 25 | — | $96.4M | ||
| Q3 25 | — | $96.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $390.0M | $114.3M | ||
| Q3 25 | $384.5M | $147.7M | ||
| Q2 25 | $376.5M | $192.3M | ||
| Q1 25 | $370.9M | $229.0M | ||
| Q4 24 | $363.8M | $256.8M | ||
| Q3 24 | $362.3M | $201.0M | ||
| Q2 24 | $353.5M | $215.2M | ||
| Q1 24 | $350.0M | $223.9M |
| Q4 25 | $3.3B | $327.7M | ||
| Q3 25 | $3.4B | $372.8M | ||
| Q2 25 | $3.3B | $313.5M | ||
| Q1 25 | $3.2B | $327.3M | ||
| Q4 24 | $3.1B | $351.2M | ||
| Q3 24 | $2.9B | $217.6M | ||
| Q2 24 | $2.9B | $222.0M | ||
| Q1 24 | $2.9B | $227.6M |
| Q4 25 | — | 0.84× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $26.6M | $-43.5M |
| Free Cash FlowOCF − Capex | $24.4M | — |
| FCF MarginFCF / Revenue | 83.6% | — |
| Capex IntensityCapex / Revenue | 7.5% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $46.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $26.6M | $-43.5M | ||
| Q3 25 | $16.4M | $-47.0M | ||
| Q2 25 | $4.9M | $-39.6M | ||
| Q1 25 | $2.3M | $-40.7M | ||
| Q4 24 | $39.0M | $42.0M | ||
| Q3 24 | $11.9M | $-14.5M | ||
| Q2 24 | $14.6M | $-7.3M | ||
| Q1 24 | $8.2M | $-6.7M |
| Q4 25 | $24.4M | — | ||
| Q3 25 | $16.2M | $-47.2M | ||
| Q2 25 | $3.8M | $-39.6M | ||
| Q1 25 | $1.6M | $-40.8M | ||
| Q4 24 | $34.9M | $41.7M | ||
| Q3 24 | $11.9M | $-14.6M | ||
| Q2 24 | $12.8M | $-7.3M | ||
| Q1 24 | $6.0M | $-6.8M |
| Q4 25 | 83.6% | — | ||
| Q3 25 | 53.2% | -145.4% | ||
| Q2 25 | 13.1% | -252.2% | ||
| Q1 25 | 6.0% | -512.1% | ||
| Q4 24 | 133.2% | 48.2% | ||
| Q3 24 | 46.8% | -706.3% | ||
| Q2 24 | 53.1% | -1463.4% | ||
| Q1 24 | 25.2% | — |
| Q4 25 | 7.5% | 0.0% | ||
| Q3 25 | 0.8% | 0.6% | ||
| Q2 25 | 3.7% | 0.3% | ||
| Q1 25 | 2.8% | 1.1% | ||
| Q4 24 | 15.5% | 0.3% | ||
| Q3 24 | 0.1% | 6.8% | ||
| Q2 24 | 7.3% | 7.6% | ||
| Q1 24 | 9.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | 0.30× | — | ||
| Q4 24 | — | 0.84× | ||
| Q3 24 | 1.52× | — | ||
| Q2 24 | 2.33× | — | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCB
Segment breakdown not available.
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
